This site is intended for healthcare professionals
  • Home
  • /
  • News
  • /
  • FDA approvesTecentriq as a first-line monotherapy ...
News

FDA approvesTecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer.- Genentech/Roche

Read time: 1 mins
Last updated:21th May 2020
Published:20th May 2020
Condition: Non Small Cell Lung Cancer
Type: drug
Register now for full access to medthority.com